Amgen’s Bispecific Blinatumomab May Be Ready For Leukemia Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Single-arm, Phase II data in relapsed acute lymphoblastic leukemia could suffice, firm says, for what would be the first-ever U.S. approval of an engineered bispecific antibody.
You may also be interested in...
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
Acute Lymphoblastic Leukemia Poised To Be First, Fast Driver Of CAR Immunotherapy
Given high complete response rates in early studies showcased at the American Society of Hematology’s recent annual meeting, acute lymphoblastic leukemia is a likely launch indication for chimeric antigen receptor immunotherapy. But while the results in B-cell malignancies are very promising so far, autologous CAR therapies are complex, and toxicities need to be carefully managed.
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).